Succinylcholine: Nursing Drug Guide, Hyperkalemia & NCLEX Review

ANECTINE (succinylcholine chloride injection) is a reference U.S. brand; many facilities stock generic succinylcholine 20 mg/mL and 100 mg/mL vials. Institutional concentrations and packaging vary—verify total mg per container before drawing.

Confirm the MAR lists succinylcholine—not a nondepolarizing agent—before RSI. Strength confusion between neuromuscular blockers is a documented high-alert error.

Succinylcholine is indicated as an adjunct to general anesthesia to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It remains common for rapid sequence intubation when hyperkalemia risk has been ruled out.

↔On a small screen, swipe or scroll sideways to see the full table.

Succinylcholine is a depolarizing neuromuscular blocking agent structurally related to acetylcholine. It binds nicotinic receptors at the motor end-plate, causing persistent depolarization, fasciculations, and flaccid paralysis. Metabolism by plasma cholinesterase (butyrylcholinesterase) is rapid in most patients.

Extrajunctional receptor upregulation after burns, denervation, prolonged immobilization, or muscular dystrophy increases potassium release with each depolarization—this is the pharmacologic basis for fatal hyperkalemia. Pair every dose plan with a structured respiratory assessment and continuous cardiac monitoring during RSI.

Onset and duration (typical adults)

↔On a small screen, swipe or scroll sideways to see the full table.

Use prescribing information and facility policy only. Verify weight, concentration, and route before every administration.

↔On a small screen, swipe or scroll sideways to see the full table.

Pretreatment checks

• Screen personal or family history of malignant hyperthermia
• Ask about major burns, crush injury, denervation, or muscular dystrophy—especially in children
• Confirm intubation equipment, ventilator, and resuscitation medications are immediately available
• Verify adequate anesthesia or sedation is co-administered—succinylcholine does not sedate
• Establish continuous ECG and pulse oximetry before IV push

Contraindications (label)

• Personal or family history of malignant hyperthermia
• Skeletal muscle myopathies (e.g., Duchenne muscular dystrophy)
• Known hypersensitivity to succinylcholine
• After the acute phase of major burns, crush injuries, and denervation injuries (upregulated receptors)

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Patients with myasthenia gravis have unpredictable response—coordinate closely with anesthesia and use nerve stimulator per protocol.

1. Independent double-check drug name, dose, concentration, route, and patient weight
2. Confirm burn/MH/denervation screen documented in perioperative record
3. Administer IV push over seconds per institutional RSI protocol with continuous monitoring
4. Secure airway and ventilate immediately—do not leave the patient unobserved during onset
5. Document exact time, dose, fasciculations, and immediate ECG/hemodynamic response

Follow high-alert medication administration workflow and complete medication reconciliation on perioperative handoffs so duplicate neuromuscular blocker orders are caught.

Succinylcholine is for intravenous or intramuscular use only. Solutions are acidic; avoid mixing with alkaline solutions (e.g., barbiturates) in the same syringe per compatibility guidance.

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

• Peaked T waves, flattened P waves, widening QRS, or sine-wave pattern after dosing
• Sudden hypotension or bradycardia progressing to pulseless arrest after IV push
• Masseter spasm, rigidity, rising EtCO2, and tachycardia during volatile anesthesia (MH concern)
• Dark urine, rising CK, and muscle weakness in a child after emergency RSI
• Apnea beyond expected duration—possible pseudocholinesterase deficiency

Overdose manifests as prolonged neuromuscular block and apnea. Hyperkalemia overdose pattern is cardiovascular collapse. Primary treatment is airway control, mechanical ventilation, and hemodynamic support until spontaneous recovery or reversal of hyperkalemia per protocol.

1. Maintain patent airway and ventilate; support circulation per resuscitation protocol
2. Treat hyperkalemia per institutional electrolyte/emergency protocol (calcium, insulin/dextrose, beta-agonist, dialysis as indicated)
3. For malignant hyperthermia: stop volatile agents and succinylcholine; activate MH cart and dantrolene protocol
4. Phase II block: use neostigmine with anticholinergic only after peripheral nerve stimulator confirms Phase II block and spontaneous twitch recovery has plateaued per labeling
5. Bradycardia in children may respond to atropine per anesthesia direction
6. Contact poison control or medical toxicology services per facility protocol and local emergency guidance for prolonged paralysis

↔On a small screen, swipe or scroll sideways to see the full table.

• Continuous ECG for hyperkalemia patterns and arrhythmia
• Serial potassium—compare to potassium laboratory reference and facility critical values
• End-tidal CO2, oxygenation, and ventilator synchrony during and after block
• CK and urine color when rhabdomyolysis is suspected in pediatric RSI
• Temperature and EtCO2 trend when MH is possible

Obtain arterial blood gas when ventilation or acid-base status is uncertain after a hyperkalemia event.

• Explain that muscle-relaxing medication is given only when the team can breathe for you with a machine
• Reassure that anesthesia is separate from the paralytic—protocol aims for unconsciousness before paralysis
• After surgery, teach that temporary soreness or weakness may occur while recovery is monitored
• Instruct families to report family history of MH or unexpected death under anesthesia
• Advise reporting new muscle pain, dark urine, or breathing difficulty after emergency intubation

Neuromuscular blocking agents are among the most dangerous wrong-drug errors in hospitals. Succinylcholine must never be administered outside monitored settings with ventilatory support ready.

• Store away from general ward injectables; keep cap and labeling intact
• Never administer from unlabeled syringes—confirm product name aloud during independent double-check
• Distinguish 20 mg/mL vs 100 mg/mL concentrations to prevent 5× dosing errors
• Separate depolarizing and nondepolarizing agents in anesthesia trays

Do not give and contact the prescriber/pharmacist/anesthesia team when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

↔On a small screen, swipe or scroll sideways to see the full table.

Practice NCLEX-style clinical judgment practice with priority action, SATA cue recognition, trend interpretation, matrix urgency classification, and documentation cloze items focused on succinylcholine hyperkalemia, burn contraindications, and malignant hyperthermia vigilance. Review the case tabs (MAR, Labs, History, Nursing notes) before answering.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.